Tegomil fumarate

Tegomil fumarate
Clinical data
Trade namesRiulvy
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • dimethyl 3,6,9-trioxaundecane-1,11-diyl di((2E)-but-2-enedioate)
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC18H26O11
Molar mass418.395 g·mol−1
3D model (JSmol)
SMILES
  • COC(=O)/C=C/C(=O)OCCOCCOCCOCCOC(=O)/C=C/C(=O)OC
InChI
  • InChI=1S/C18H26O11/c1-23-15(19)3-5-17(21)28-13-11-26-9-7-25-8-10-27-12-14-29-18(22)6-4-16(20)24-2/h3-6H,7-14H2,1-2H3/b5-3+,6-4+
  • Key:XBRIIHOHDRTZMQ-GGWOSOGESA-N

Tegomil fumarate sold under the brand name Riulvy, is a medication used for the treatment of relapsing remitting multiple sclerosis.[1] It is taken by mouth.[1]

The mechanism of action of tegomil fumarate is not fully understood but it is thought to act via its main active metabolite monomethyl fumarate.[1] This metabolite activates the NRF2 transcriptional pathway, which reduces inflammation and modulates the activity of immune cells, thereby protecting the cells of the central nervous system from damage.[1]

Tegomil fumarate was authorized for medical use in the European Union in July 2025.[2]

Medical uses

Tegomil fumarate is indicated for the treatment of people aged thirteen years of age and older with relapsing remitting multiple sclerosis.[1]

Society and culture

In May 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Riulvy, intended for the treatment of adults and children from 13 years of age with relapsing remitting multiple sclerosis.[1] The applicant for this medicinal product is Neuraxpharm Pharmaceuticals, S.L.[1] Riulvy is a hybrid medicine of Tecfidera, which has been authorized in the EU since January 2014.[1] Riulvy contains a different active substance but acts via the same active metabolite as Tecfidera, monomethyl fumarate.[1] Tegomil fumarate was authorized for medical use in the European Union in July 2025.[1][2]

Names

Tegomil fumarate is the international nonproprietary name.[3]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 "Riulvy EPAR". European Medicines Agency (EMA). 23 May 2025. Retrieved 15 June 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. 1 2 3 "Riulvy PI". Union Register of medicinal products. 7 August 2025. Retrieved 18 September 2025.
  3. ↑ World Health Organization (2024). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 91". WHO Drug Information. 38 (1). hdl:10665/378096.


This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.